Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

April 2nd 2025

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

April 2nd 2025

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL

April 2nd 2025

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Orca-T Boosts cGVHD-Free Survival vs Allo-HSCT in Advanced Hematologic Malignancies

April 2nd 2025

Orca-T improved moderate-to-severe cGVHD–free survival vs conventional allogenic transplant in advanced hematologic malignancies.

Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL

April 1st 2025

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

Inotuzumab Ozogamicin–Based Bridging Therapy Boosts Obe-Cel Outcomes in B-Cell ALL

April 1st 2025

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse

April 1st 2025

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

AFM28 Shows Preliminary Activity in CD123+ Relapsed/Refractory AML

April 1st 2025

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

Dr Politikos on the Immune Reconstitution Profiles of Orca-T and CD34 Allograft Recipients in Hematologic Malignancies

April 1st 2025

Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.

TDI01 Demonstrates Preliminary Efficacy and Tolerability in Moderate-to-Severe cGVHD

March 31st 2025

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma

March 31st 2025

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD

March 31st 2025

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Orca-T Is Associated With Retrospective OS Improvement vs Post-Transplant Cyclophosphamide in Advanced Hematologic Malignancies

March 31st 2025

Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.

Orca-T Stands Out From CD34 Grafts, Showing Lower Rates of EBV, CMV Reactivation in Hematologic Malignancies

March 31st 2025

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas

March 31st 2025

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

March 31st 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.